This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2025
  • /
  • 2
  • /
  • 177Lu-Edotreotide Extended PFS
News

177Lu-Edotreotide Extended PFS

Read time: 1 mins
Published:3rd Feb 2025
"

The proprietary, synthetic, targeted radiotherapeutic agent 177 Lutetium edotreotide (ITM-11; 177Lu-edotreotide) extended progression-free survival (PFS) vs everolimus (Afinitor) in patients with inoperable, progressive, grade 1 or 2 gastro- enteropancreatic neuroendocrine tumors (GEP-NETs), meeting the primary end point of the phase III COMPETE trial (NCT03049189)

The treatment was also well tolerated with favorable safety data according to the drug’s developer, ITM, who intends to submit the findings for presentation at an upcoming medical meeting. The company also expects to discuss a pathway toward a new drug application submission with the FDA in 2025.

“With COMPETE, this marks the first time that a targeted radiopharmaceutical therapy has demonstrated improved progression-free survival compared to a targeted molecular therapy, everolimus, in patients with grade 1 and grade 2 GEP-NET tumors in a phase III  clinical trial. The patients included represent a real-life scenario, and the COMPETE study evaluates the important question of which therapy might be used first to provide greater benefit to patients,” Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d’Hebron University Hospital, Barcelona, stated in a news release. “As a clinician, I am highly encouraged by these data and look forward to seeing further results.”

177Lu-edotreotide is a radiolabeled peptide conjugate that releases β radiation to SSTR-positive tumor cells via intravenous administration, sparing healthy organs and tissue. 177Lu-edotreotide is made up of non-carrier-added lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic somatostatin receptor (SSTR) agonist.

In 2022, the FDA granted fast track designation to 177Lu-edotreotide for the treatment of patients with GEP-NETs based in part on data from the COMPETE trial.

COMPETE is a prospective, randomized, controlled, open-label phase III trial evaluating the efficacy and safety of 177Lu-edotreotide vs standard-of-care (SOC) treatment with everolimus. The trial enrolled 309 patients with grade 1 or grade 2 inoperable, progressive, SSTR-positive NETs of gastroenteric or pancreatic origin with a Ki-67 index of 20% or less.Patients were randomly assigned 2:1 to receive 7.5 GBq of 177Lu-edotreotide with a nephroprotective amino acid solution every 3 months for up to 4 cycles, or 10 mg of everolimus daily for up to 30 months, or until disease progression. The trial’s secondary end points include objective response rate, overall survival, and quality of life assessments. Notably, dosimetry was used to evaluate the dose of 177Lu-edotreotide that was absorbed in tumors vs that in healthy tissue to augment safety and efficacy assessments. Evaluation of the dosimetry data, secondary end points, and supplementary subgroup analyses are underway.

In addition to the COMPETE trial, 177Lu-edotreotide is being studied in the phase III COMPOSE trial (NCT04919226) in patients with well-differentiated, aggressive grade 2 or grade 3, SSTR-positive GEP-NETs. The prospective, randomized, controlled, open-label trial is comparing the efficacy, safety, and patient-reported outcomes of 177Lu-edotreotide as first- or second-line treatment with physician’s choice of SOC chemotherapy.

Additionally, 177Lu-edotreotide is being tested in the phase 1 KinLET trial (NCT06441331) in pediatric patients with SSTR-positive tumors and the phase III investigator-sponsored LEVEL trial (NCT05918302) in patients with lung and thymus NETs

Condition: Gastroentero-pancreatic neuroendocrine tumors
Type: drug
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.